Research programme: anti-CD44 variant monoclonal antibodies - MaimoniDex RA

Drug Profile

Research programme: anti-CD44 variant monoclonal antibodies - MaimoniDex RA

Alternative Names: Anti-CD44 variant monoclonal antibodies research programme - Maimonidex RA; MD-101

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MaimoniDex RA
  • Class Monoclonal antibodies
  • Mechanism of Action CD44 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Israel (Injection, Injection)
  • 23 Sep 2005 MaimoniDex RA and Abmaxis have entered into an agreement to jointly develop a human monoclonal antibody for rheumatoid arthritis and other inflammatory diseases
  • 15 Jul 2005 Anti-CD44 variant monoclonal antibodies are available for partnering
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top